Aptevo Therapeutics Inc.
| NASDAQ: APVO | Healthcare / Biotechnology / USA |
| 25.32 | -0.5400 | -2.09% | Vol 24.88K | 1Y Perf 609.86% |
| Apr 16th, 2021 16:00 DELAYED |
| BID | 25.22 | ASK | 25.91 | ||
| Open | 26.00 | Previous Close | 25.86 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 65.67 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 159.36 | Finscreener Ranking | ★+ 45.43 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | + 38.16 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★ 33.67 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 112.65M | Earnings Rating | Neutral | |
| Price Range Ratio 52W % | 38.45 | Earnings Date | 12th May 2021 |
Today's Price Range 24.0026.70 | 52W Range 3.6660.00 | 5 Year PE Ratio Range -0.600022.70 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -1.29% | ||
| 1 Month | -31.88% | ||
| 3 Months | -22.12% | ||
| 6 Months | 262.75% | ||
| 1 Year | 609.86% | ||
| 3 Years | 487.47% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -98.66 | |||
ROE last 12 Months | -120.39 | |||
ROA (5Y Avg) | -86.76 | |||
ROA last 12 Months | -31.78 | |||
ROC (5Y Avg) | -62.97 | |||
ROC last 12 Months | -70.82 | |||
Return on invested Capital Q | -17.85 | |||
Return on invested Capital Y | -44.91 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 0.90 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -5.10 | ||||
| 7.15 | ||||
| 25.38 | ||||
| - | ||||
| -6.50 | ||||
| -8.65 | ||||
| 7.15 | ||||
| 3.73 | ||||
| 106.15M | ||||
| Forward PE | -3.56 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.90 | ||||
| 3.30 | ||||
| 0.57 | ||||
| 1.65 | ||||
| - | ||||
| Leverage Ratio | 2.80 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 82.60 | ||||
| -88.00 | ||||
| -83.40 | ||||
| -573.50 | ||||
| -68.62 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 4.31M | ||||
| 0.97 | ||||
| -38.06 | ||||
| -25.32 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2020 | -2.05 | -2.15 | -4.88 |
| Q02 2020 | -2.27 | -2.10 | 7.49 |
| Q01 2020 | -2.55 | -2.42 | 5.10 |
| Q03 2019 | -3.36 | -3.22 | 4.17 |
| Q02 2019 | -5.32 | -4.20 | 21.05 |
| Q01 2019 | -6.72 | -6.16 | 8.33 |
| Q03 2018 | -8.26 | -7.84 | 5.08 |
| Q02 2018 | -0.65 | -0.58 | 10.77 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2020 FY | -8.78 | 0.00 | - |
| 3/2021 QR | -1.62 | 4.71 | Positive |
| 6/2021 QR | -1.86 | -2.20 | Negative |
| 12/2021 FY | -7.20 | -22.03 | Negative |
| Next Report Date | 12th May 2021 |
| Estimated EPS Next Report | -1.62 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 24.88K |
| Shares Outstanding | 4.45M |
| Trades Count | 447 |
| Dollar Volume | 6.26M |
| Avg. Volume | 59.47K |
| Avg. Weekly Volume | 24.52K |
| Avg. Monthly Volume | 36.97K |
| Avg. Quarterly Volume | 57.75K |
Aptevo Therapeutics Inc. (NASDAQ: APVO) stock closed at 25.32 per share at the end of the most recent trading day (a -2.09% change compared to the prior day closing price) with a volume of 24.88K shares and market capitalization of 112.65M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 80 people. Aptevo Therapeutics Inc. CEO is Marvin L. White.
The one-year performance of Aptevo Therapeutics Inc. stock is 609.86%, while year-to-date (YTD) performance is -30.91%. APVO stock has a five-year performance of %. Its 52-week range is between 3.66 and 60, which gives APVO stock a 52-week price range ratio of 38.45%
Aptevo Therapeutics Inc. currently has a PE ratio of -5.10, a price-to-book (PB) ratio of 7.15, a price-to-sale (PS) ratio of 25.38, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -31.78%, a ROC of -70.82% and a ROE of -120.39%. The company’s profit margin is -68.62%, its EBITDA margin is -83.40%, and its revenue ttm is $4.31 Million , which makes it $0.97 revenue per share.
Of the last four earnings reports from Aptevo Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.62 for the next earnings report. Aptevo Therapeutics Inc.’s next earnings report date is 12th May 2021.
The consensus rating of Wall Street analysts for Aptevo Therapeutics Inc. is Strong Buy (1), with a target price of $65.67, which is +159.36% compared to the current price. The earnings rating for Aptevo Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aptevo Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aptevo Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 11.54, ATR14 : 2.83, CCI20 : -76.33, Chaikin Money Flow : -0.36, MACD : -2.60, Money Flow Index : 37.72, ROC : -10.21, RSI : 43.12, STOCH (14,3) : 22.46, STOCH RSI : 0.72, UO : 47.58, Williams %R : -77.54), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aptevo Therapeutics Inc. in the last 12-months were:
Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a biosciences company. The company is engaged in the discovery, development, commercialization and sale of novel oncology and hematology therapeutics. Its pipeline product includes Otlertuzumab, APVO414, Multiple ADAPTIR Candidates, ALG.APV-527, APVO436 and APVO210.
CEO: Marvin L. White
Telephone: +1 206 838-0500
Address: 2401 4th Avenue, Seattle 98121, WA, US
Number of employees: 80
